StockGlow

Dimerix Limited (DXB.AX)

Develops kidney and lung disease treatments using a proprietary drug discovery platform

0.24-0.04%Healthcare
Compare DXB.AX with
StockGlow Score
40
Neutral
BearishBullish
1 year ago-50.0%

The outlook

Dimerix trades at $0.24, sitting near its 52-week lows with mixed momentum against key moving averages. Analyst coverage shows a notably bullish average price target sitting roughly 690% above the current price, though overall sentiment remains neutral. The stock presents a wide disconnect between current price levels and consensus targets.

What’s behind the score

Price trendMixed vs its moving averages
52-week range16% of the way from its 52-week low to high
Price targetAvg target +690% vs current price
Market cap
$144.1M
52-wk high
0.67
52-wk low
0.16
50-day avg
0.21
200-day avg
0.39
Trailing P/E
—

Similar stocks

OCC.AXOrthocell Limited$0.72+0.70%NEU.AXNeuren Pharmaceuticals Limited$17.13+0.47%CYP.AXCynata Therapeutics Limited$0.01+0.00%ONE.AXOneview Healthcare PLC$0.15-6.25%ACW.AXActinogen Medical Limited$0.04-4.88%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy